Novo Nordisk India launches world’s first and only GLP-1 RA, oral semaglutide
Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach
Oral semaglutide is a co-formulation of GLP-1RA semaglutide with an absorption enhancer SNAC which protects semaglutide from undergoing degradation in the stomach
These results will be presented on 21 January at the 2022 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium
Industry Report highlights the opportunities and need for multiple sectoral collaboration through 12 actionable recommendations under 6 thematic areas
New capabilities on Philips Image Guided therapy mobile C-arm system – Zenition – and collaboration with Cydar offer the latest advances in endovascular treatment
Extending nonsurgical treatment options for Failing Pulmonic Valve in patients with congenital heart disease using Transcatheter Pulmonary Valve
Prof Karikó's research was most notably used by Pfizer/BioNTech and Moderna to build COVID-19 mRNA vaccines
As part of Daiichi Sankyo’s 2030 vision, it plans to strengthen its oncology portfolio
The tele-heath market in India is expected to touch US $ 5.4 billion by 2025 and the adoption of tele-health has accelerated with the onset of Covid-19 in 2020. We caught up with Jeya Kumar, Founder and MD, RaphaCure, a prominent player in this segment and he outlined the opportunities that lie ahead for this segment
The company has 47 ANDA's pending approval with the U.S.FDA
Narayanan to lead SeQuent through next phase of consolidation and growth
Subscribe To Our Newsletter & Stay Updated